Literature DB >> 10510215

The pharmacology of bisphosphonates and new insights into their mechanisms of action.

R G Russell1, M J Rogers, J C Frith, S P Luckman, F P Coxon, H L Benford, P I Croucher, C Shipman, H A Fleisch.   

Abstract

Bisphosphonates are chemically stable analogs of inorganic pyrophosphate, which are resistant to breakdown by enzymatic hydrolysis. The biological effects of bisphosphonates on calcium metabolism were originally ascribed to their physico-chemical effects on hydroxyapatite crystals. Although such effects may contribute to their overall action, their effects on cells are probably of greater importance, particularly for the more potent compounds. Remarkable progress has been made in increasing the potency of bisphosphonates as inhibitors of bone resorption, and the most potent compounds in current use are characterized by the presence of a nitrogen atom at critical positions in the side chain which, together with the bisphosphonate moiety itself, seems to be essential for maximal activity. As a class the bisphosphonates offer a very effective means of treating Paget's disease.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10510215     DOI: 10.1002/jbmr.5650140212

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  48 in total

1.  Bisphosphonate Use and Prevalence of Valvular and Vascular Calcification in Women MESA (The Multi-Ethnic Study of Atherosclerosis).

Authors:  Sammy Elmariah; Joseph A C Delaney; Kevin D O'Brien; Matthew J Budoff; Jens Vogel-Claussen; Valentin Fuster; Richard A Kronmal; Jonathan L Halperin
Journal:  J Am Coll Cardiol       Date:  2010-11-16       Impact factor: 24.094

2.  New insights into human farnesyl pyrophosphate synthase inhibition by second-generation bisphosphonate drugs.

Authors:  D Fernández; R Ramis; J Ortega-Castro; R Casasnovas; B Vilanova; J Frau
Journal:  J Comput Aided Mol Des       Date:  2017-06-19       Impact factor: 3.686

Review 3.  Bone disease in multiple myeloma.

Authors:  Øyvind Hjertner; Therese Standal; Magne Børset; Anders Sundan; Anders Waage
Journal:  Med Oncol       Date:  2006       Impact factor: 3.064

Review 4.  Bisphosphonates: effects on osteoblast.

Authors:  Nicola Maruotti; Addolorata Corrado; Anna Neve; Francesco Paolo Cantatore
Journal:  Eur J Clin Pharmacol       Date:  2012-02-09       Impact factor: 2.953

Review 5.  Regulation of osteoclast polarization.

Authors:  Naoyuki Takahashi; Sadakazu Ejiri; Shigeru Yanagisawa; Hidehiro Ozawa
Journal:  Odontology       Date:  2007-07-25       Impact factor: 2.634

6.  Role of neridronate on MCF-7 estrogen dependent breast cancer model of bone metastasis: a preliminary study.

Authors:  Vanessa Nicolin; Paola Narducci; Renato Bareggi
Journal:  Invest New Drugs       Date:  2009-10-02       Impact factor: 3.850

Review 7.  Bisphosphonate-related osteonecrosis of the jaw in non-malignant bone disease.

Authors:  Peter K Wong; Gelsomina L Borromeo; John D Wark
Journal:  Rheumatol Int       Date:  2013-05-08       Impact factor: 2.631

8.  Case report of spontaneous, nonspinal fractures in a multiple myeloma patient on long-term pamidronate and zoledronic acid.

Authors:  Greg Wernecke; Surena Namdari; Surena Namduri; Edward F DiCarlo; Robert Schneider; Joseph Lane
Journal:  HSS J       Date:  2008-07-16

9.  Zoledronic acid up-regulates bone sialoprotein expression in osteoblastic cells through Rho GTPase inhibition.

Authors:  Michaël Chaplet; Cédric Detry; Christophe Deroanne; Larry W Fisher; Vincent Castronovo; Akeila Bellahcéne
Journal:  Biochem J       Date:  2004-12-15       Impact factor: 3.857

Review 10.  Progress in osteoporosis and fracture prevention: focus on postmenopausal women.

Authors:  Kenneth G Saag; Piet Geusens
Journal:  Arthritis Res Ther       Date:  2009-10-14       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.